FierceBiotech4d
Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh's preclinical drug
Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...
Is Merck the Next Big Weight-Loss Stock?
And that's why Merck could credibly become the next big weight-loss stock. Before you rush to go buy shares of Merck, ...
Yahoo Finance3d
MSD makes obesity play in up to $2bn deal for Hansoh’s GLP-1RA asset
Merck & Co (MSD) has entered an exclusive global licence agreement with China-based Hansoh Pharma for a preclinical oral ...
STAT4d
Pharmalittle: We’re reading about a Merck deal for an obesity pill, a departing FDA official, and more
Merck signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's oral obesity drug ...
Seeking Alpha on MSN4d
Merck-Hansoh deal for oral GLP-1 hurts obesity drug developers
Viking Therapeutics (NASDAQ:VKTX) and Structure Therapeutics (NASDAQ:GPCR) were among notable decliners on Wednesday after ...
Why Viking Therapeutics Tumbled by More Than 10% This Week
According to data compiled by S&P Global Market Intelligence, the biotech's share price fell by just over 10% over the period ...
FiercePharma2d
Fierce Pharma Asia—Merck's oral GLP-1 play; Astellas' gene therapy deal; Betta's FDA nod
Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a ...